1. Home
  2. DNUT vs MYGN Comparison

DNUT vs MYGN Comparison

Compare DNUT & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Krispy Kreme Inc.

DNUT

Krispy Kreme Inc.

HOLD

Current Price

$3.35

Market Cap

602.2M

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$4.68

Market Cap

481.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DNUT
MYGN
Founded
1937
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Food Chains
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
602.2M
481.6M
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
DNUT
MYGN
Price
$3.35
$4.68
Analyst Decision
Buy
Buy
Analyst Count
6
8
Target Price
$4.72
$7.64
AVG Volume (30 Days)
2.4M
1.8M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
1.03%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,522,616,000.00
$771,400,000.00
Revenue This Year
$0.48
$7.19
Revenue Next Year
$3.33
$5.64
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2.33
52 Week Low
$2.58
$3.76
52 Week High
$5.73
$9.48

Technical Indicators

Market Signals
Indicator
DNUT
MYGN
Relative Strength Index (RSI) 47.29 44.59
Support Level $3.05 $4.24
Resistance Level $3.48 $5.69
Average True Range (ATR) 0.17 0.32
MACD -0.01 0.00
Stochastic Oscillator 31.30 32.04

Price Performance

Historical Comparison
DNUT
MYGN

About DNUT Krispy Kreme Inc.

Krispy Kreme Inc is a sweet treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations across the globe. It derives maximum revenue from the U.S. segment.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: